Gregory D. Perry - 16 Jun 2022 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Reporting relationship: Director
Issuer ticker: KALA
Reported as of: 16 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2022, 16:45:38 UTC
Prior SEC filing: 02 Jun 2022
Next SEC filing: 02 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Mary Reumuth, Attorney-in-Fact

Key filing fact

Gregory D. Perry filed Form 4 for Kala Pharmaceuticals, Inc. (KALA) on 17 Jun 2022.

Key facts

This page summarizes Gregory D. Perry's Form 4 filing for Kala Pharmaceuticals, Inc. (KALA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2022, 16:45.

Change

Previous filing in this sequence was filed on 02 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 16 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $0.3600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.